Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chapel Hill, NC
Treatments:Biologic therapyHospital:Lineberger Comprehensive Cancer Center
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This phase II study involved 63 patients with advanced non-small-cell lung cancer. The median age was 60, ranging from 33 to 86 years old. Sixteen percent of the patients had never smoked.

Treatment: Patients were treated with the drug sunitinib. This biological therapy works by affecting the growth of tumors and blood vessels.

Toxicity: Two patients died from treatment-related pulmonary hemorrhage. Grade 4 toxicities included fatigue/asthenia, pain/myalgia, lymphopenia, neutropenia, and thrombocytopenia. These occurred in 5% of patients or less.

Result: The median overall survival was 5.4 months (23.4 weeks).

Support: This study was supported by Pfizer Inc., which developed/markets sunitinib as Sutent®.

Correspondence: Dr. Mark A. Socinski



Back